Cargando…
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells
Glioblastoma (GBM) is one of the most lethal cancers, having a poor prognosis and a median survival of only about 15 months with standard treatment (surgery, radiation, and chemotherapy), which has not been significantly extended in decades. GBM demonstrates remarkable cellular heterogeneity, with g...
Autores principales: | Kardani, Kimia, Sanchez Gil, Judit, Rabkin, Samuel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264819/ https://www.ncbi.nlm.nih.gov/pubmed/37325516 http://dx.doi.org/10.3389/fcimb.2023.1206111 |
Ejemplares similares
-
Herpes Simplex Virus Cell Entry Mechanisms: An Update
por: Madavaraju, Krishnaraju, et al.
Publicado: (2021) -
Herpes Simplex Virus Evasion of Early Host Antiviral Responses
por: Tognarelli, Eduardo I., et al.
Publicado: (2019) -
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
por: Ning, Jianfang, et al.
Publicado: (2014) -
Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012) -
Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions
por: Liu, Junfeng, et al.
Publicado: (2023)